MedTrace Logo

Cavilon Breast Trial: Comparison of Cavilon Durable Barrier Cream to Glycerine ("Sorbolene") Cream

NCT00193908 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 333

Last updated 2009-05-14

No results posted yet for this study

Summary

This study has patients using two different moisturising creams during radiation therapy after mastectomy. These are Cavilon and sorbolene. It is hypothesised that skin reactions may be reduced by the Cavilon cream compared to sorbolene.

Conditions

Interventions

DRUG

Cavilon (TM) Durable Barrier Cream

Cavilon (TM) Durable Barrier Cream will be applied to either the medial or the lateral side of the treated breast. Side will depend on randomisation.

DRUG

Sorbolene

Sorbolene will be applied to either the medial or the lateral side of the treated breast. Side will be determined by randomisation

RADIATION

Radiotherapy

Minimum prescribed dose to the chest wall is 45Gy in 25 fractions. Planning and Treatment is per the study protocol

Sponsors & Collaborators

  • 3M

    collaborator INDUSTRY

  • Trans Tasman Radiation Oncology Group

    lead OTHER

Principal Investigators

  • Peter Graham · St George Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2007-09-30
Completion
2008-10-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00193908 on ClinicalTrials.gov